Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Perrigo
PRGO
|
+$672M |
| 2 |
Merck
MRK
|
+$608M |
| 3 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$384M |
| 4 |
Las Vegas Sands
LVS
|
+$378M |
| 5 |
TFCFA
Twenty-First Century Fox, Inc. Class A
TFCFA
|
+$303M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ralph Lauren
RL
|
+$518M |
| 2 |
eBay
EBAY
|
+$474M |
| 3 |
Estee Lauder
EL
|
+$435M |
| 4 |
Goldman Sachs
GS
|
+$323M |
| 5 |
TechnipFMC
FTI
|
+$304M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.03% |
| 2 | Consumer Discretionary | 13.85% |
| 3 | Communication Services | 11.23% |
| 4 | Technology | 10.46% |
| 5 | Energy | 9.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Travere Therapeutics
TVTX
$5.33B
| $41.9M | 0.04% |
+1,969,819
| New | +$30.3M |
|
|
QLIK
352
DELISTED
QLIK TECHNOLOGIES INC COM STK (DE)
QLIK
| $41.9M | 0.04% |
1,575,267
-549,460
| -26% | -$15.3M |
|
353
SLM Corp
SLM
$4.86B
| $41M | 0.04% |
4,681,353
-93,207
| -2% | -$814K |
|
|
ENDP
354
DELISTED
Endo International plc
ENDP
| $40.9M | 0.04% |
595,077
+271,910
| +84% | +$19.3M |
|
|
GNMK
355
DELISTED
GenMark Diagnostics, Inc
GNMK
| $40.6M | 0.04% |
4,084,565
-24,111
| -0.6% | -$300K |
|
|
ENLC
356
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $40.4M | 0.04% |
1,191,599
+192,269
| +19% | +$7.13M |
|
|
GWR
357
DELISTED
Genesee & Wyoming Inc.
GWR
| $40.1M | 0.04% |
412,450
-997
| -0.2% | -$94.4K |
|
358
National Grid
NGG
$80.8B
| $38.8M | 0.04% |
585,140
-187,464
| -24% | -$12.1M |
|
359
Dorman Products
DORM
$3.98B
| $38.8M | 0.04% |
656,981
-37,811
| -5% | -$2.08M |
|
|
CNL
360
DELISTED
CLECO CRP (HOLDING CO)
CNL
| $38.8M | 0.04% |
766,862
| – | – |
|
|
BRCD
361
DELISTED
Brocade Communications Systems, Inc. NEW
BRCD
| $38.7M | 0.04% |
3,645,523
-347,680
| -9% | -$3.35M |
|
362
Extra Space Storage
EXR
$31.3B
| $38.4M | 0.04% |
792,522
+777,894
| +5,318% | +$36.1M |
|
|
TMH
363
DELISTED
Team Health Holdings Inc
TMH
| $38.4M | 0.04% |
859,010
+106,445
| +14% | +$4.79M |
|
|
HOLX
364
DELISTED
Hologic
HOLX
| $38.3M | 0.04% |
1,779,947
+618,709
| +53% | +$13.3M |
|
365
Freeport-McMoran
FCX
$91.2B
| $38.2M | 0.04% |
1,156,559
-28,886
| -2% | -$961K |
|
366
IMAX
IMAX
$2.61B
| $38.2M | 0.04% |
1,398,089
-396,625
| -22% | -$10.8M |
|
367
Molson Coors Class B
TAP
$7.79B
| $38.1M | 0.04% |
646,802
| – | – |
|
|
RAD
368
DELISTED
Rite Aid Corporation
RAD
| $37.8M | 0.04% |
+301,618
| New | +$36.8M |
|
369
Huron Consulting
HURN
$2.61B
| $37.5M | 0.04% |
591,887
-11,229
| -2% | -$730K |
|
|
IPXL
370
DELISTED
Impax Laboratories, Inc.
IPXL
| $37.3M | 0.04% |
1,412,410
+317,083
| +29% | +$7.92M |
|
|
UTX.PRA
371
DELISTED
UNITED TECHNOLOGIES CORP CORP UNIT (DE)
UTX.PRA
| $37.3M | 0.04% |
560,000
| – | – |
|
|
MDCO
372
DELISTED
Medicines Co
MDCO
| $37.1M | 0.04% |
1,304,736
-6,264
| -0.5% | -$207K |
|
|
DRC
373
DELISTED
DRESSER-RAND GROUP INC
DRC
| $36.9M | 0.04% |
632,164
-914,465
| -59% | -$52.1M |
|
374
Antero Resources
AR
$10.9B
| $36.7M | 0.04% |
585,678
+84,748
| +17% | +$5.02M |
|
|
SGMO
375
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $36.5M | 0.03% |
2,016,213
+108,670
| +6% | +$2.09M |
|
Similar funds
Jennison Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Jennison Associates held 826 positions worth $105B, up 2.6% from $102B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Jennison Associates's Q1 2014 filing shows 122 new, 275 increased, 321 reduced and 94 closed positions. Its largest new stake was Perrigo: 4,257,843 shares worth $659M. The largest sale was Ralph Lauren, an estimated $518M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, up from 18% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Jennison Associates's largest Q1 2014 buy was Perrigo: 4,257,843 shares worth $659M.
- Jennison Associates added most to Merck in Q1 2014, an estimated $608M increase.
- Jennison Associates's biggest Q1 2014 reduction was Estee Lauder, cutting an estimated $435M.
- Jennison Associates fully exited Ralph Lauren in Q1 2014, selling an estimated $518M.
- Jennison Associates's ten largest holdings make up 18% of its $105B portfolio in Q1 2014.
- Jennison Associates opened 122 new positions and closed 94 in Q1 2014.
- Jennison Associates's portfolio value rose 2.6% quarter-over-quarter to $105B.
Based on Jennison Associates's 13F filing for Q1 2014, filed 7 May 2014.